Inspire Medical Systems: The Moat Just Passed Its Worst-Case Stress Test

Inspire Medical Systems’ gross margin expanded to 86%, and operating cash flow totaled $82.5M over nine months, despite revenue falling 7.9% year over year. Management attributes nearly all of the shortfall to reimbursement and coding disruptions; the article argues the market is treating these headwinds as permanent, while management expects growth to resume after a permanent CPT code takes effect in January 2028.

Analysis

The key underwriting question is whether coding friction merely delays procedures or permanently diverts patients and physicians to alternatives. Delayed cases can become lost cases: referral patterns, clinic capacity, and patient willingness to wait may deteriorate before the 2028 code change, while established CPAP treatment remains a readily available substitute. That creates a risk that the eventual reimbursement fix restores access without restoring the prior growth trajectory.

The reported margin and cash-flow resilience argues against an immediate balance-sheet stress thesis, but it does not establish that operating leverage is protected if procedure volumes remain weak; verify cash-flow components and expense trends. Management’s attribution of the shortfall to administration is not independently proven by the figures provided. Nor does the article establish that valuation already discounts a permanent impairment.

Near term, look for evidence in procedure volumes, denial/appeal rates, payer coverage, and guidance—not the 2028 date alone. Over 6–18 months, sustained referral losses or physician substitution would matter more than the eventual code’s formal implementation. A delay or restrictive interpretation of the code would extend the uncertainty; improved authorization and conversion data could support a recovery before then. The thesis is falsified by continued volume deterioration, further guidance cuts, or margin erosion despite coding progress.

Key Decisions for Investors

• Keep INSP on a conditional long watchlist rather than treating the reimbursement resolution as established. Consider a small, staged position only if procedure and authorization trends stabilize; the article provides no valuation evidence to justify calling the shares mispriced.
• Use the next 1–3 months to verify procedure growth, payer denials/appeals, referral activity, and expense leverage. If revenue weakness persists while these indicators fail to improve, reduce exposure rather than waiting solely for the 2028 code change.
• Track CPAP and other sleep-apnea treatment alternatives for evidence that delayed Inspire candidates are switching permanently. Rising substitution would weaken the recovery case even if reimbursement rules improve.
• Reassess on any code implementation delay or restrictive payer interpretation, and on guidance revisions. A sustained decline in procedure volume or gross margin is a thesis-break signal; improving access and conversion would support adding incrementally.